BioLineRx Ltd. (NASDAQ:BLRX) has received an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company. BioLineRx’s rating score has declined by 100% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a 1-year consensus price objective of $4.00 for the company and are predicting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also assigned BioLineRx an industry rank of 80 out of 265 based on the ratings given to its competitors.

Several brokerages have recently weighed in on BLRX. Maxim Group cut shares of BioLineRx from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $4.00 to $1.00 in a research note on Monday, August 8th. Roth Capital reissued a “buy” rating and issued a $7.00 target price on shares of BioLineRx in a report on Sunday, August 14th. Finally, Zacks Investment Research lowered shares of BioLineRx from a “buy” rating to a “hold” rating in a report on Thursday, June 16th.

A hedge fund recently raised its stake in BioLineRx stock. Menta Capital LLC increased its position in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 11.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 98,917 shares of the company’s stock after buying an additional 10,400 shares during the period. Menta Capital LLC owned 0.18% of BioLineRx worth $101,000 as of its most recent filing with the SEC. 12.47% of the stock is currently owned by institutional investors and hedge funds.

Shares of BioLineRx (NASDAQ:BLRX) opened at 0.957 on Wednesday. The company’s market capitalization is $54.00 million. The firm’s 50-day moving average is $0.86 and its 200 day moving average is $0.93. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.88.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. Equities analysts expect that BioLineRx will post ($0.26) EPS for the current year.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.